BML-210 (537034-17-6) is a novel non-hydroxamic acid HDAC inhibitor. IC50=5-10 μM (HeLa nuclear extract). Induces growth inhibition, proapoptotic and differentiation effects on human leukemia cell lines.
1) Savickiene, et al. (2006), The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines; Eur. J. Pharmacol. 549 9
2) Herman, et al. (2006), Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia; Nature Chem. Biol. 10 551